NCT02487095View on ClinicalTrials.gov

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

July 30, 2015

Primary Completion Date

February 24, 2021

Study Completion Date

December 26, 2024

Conditions
Carcinoma, Non-Small -Cell LungOvarian NeoplasmsSmall Cell Lung CarcinomaUterine Cervical NeoplasmsCarcinoma, NeuroendocrineExtrapulmonary Small Cell Cancer
Interventions
DRUG

Topotecan

Topotecan (in combination with VX-970 (M6620) administered by intravenous (IV) Days 1-5 in a 21 day cycle, until disease progression or development of intolerable side effects.

DRUG

VX-970 (M6620)

VX-970 (M6620 (in combination with Topotecan) administered by intravenous (IV) Day 5 or Days 2 and 5 in a 21 day cycle, until disease progression or development of intolerable side effects.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02487095 - Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers | Biotech Hunter | Biotech Hunter